Kaposi sarcoma (KS) is a tumour of endothelial origin caused by KS herpesvirus (KSHV) infection 28 and suggested to originate from lymphatic endothelial cells (LECs). While KSHV establishes latency 29 in virtually all susceptible cell types, LECs support a spontaneous lytic gene expression program with 30 high viral genome copies and release of infectious virus. Here, we investigated the role of PROX1, 31 SOX18 and COUPTF2, drivers of lymphatic endothelial fate during embryogenesis, in this unique 32 KSHV infection program. We found that these factors were co-expressed in KS tumours with the 33 viral lytic marker K8.1, and that SOX18 and PROX1 regulate KSHV infection via two independent 34 mechanisms. SOX18 binds to the viral origins of replication and its depletion or chemical inhibition 35 significantly reduced the KSHV genome copies in LECs. PROX1 interacts with ORF50, the initiator 36 of the lytic cascade, increases lytic gene expression and virus production and its depletion reduces 37 KSHV spontaneous lytic reactivation. Upon lytic replication, PROX1 binds to the KSHV genome in 38 the promoter region of ORF50 and enhances its transactivation activity. These results demonstrate 39 the importance of two endothelial transcription factors in the regulation of the KSHV life cycle and 40 introduce SOX18 inhibition as a potential, novel therapeutic modality for KS. 41 42 43 KEYWORDS 44 Kaposi sarcoma, KSHV, herpesvirus, K8.1, transcription factors, PROX1, SOX18, lymphatic 45 endothelial cells, viral genome replication, viral reactivation. 46 47 3 MAIN 48
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(10 5 -10 6 IU/ml) was observed only from KLECs, and not from KBECs infected with two different 137 KSHV strains, rKSHV.219 and WT-KSHV ( Fig.2f, Supplementary Fig.2d ). 138
Thus, SOX18, PROX1 and COUPTF2 were all highly expressed in KLECs, which, compared to the 139 latently-infected KBECs, expressed lytic markers and produced high titers. This points to KLECs as 140 a physiologically-relevant model to study SOX18, PROX1 and COUPTF2 in KSHV infection. 
SOX18 and PROX1 regulate KSHV infection through different mechanisms 168
To investigate SOX18, PROX1 and COUPTF2 in KSHV infection, KLECs treated with control 169 siRNA or siRNAs targeting these TFs for 72h were analysed for viral mRNAs, protein expression 170 and titers ( Fig.3a-c, Supplementary Fig.3a-d ). PROX1 and SOX18 depletion significantly decreased 171 the lytic transcript and protein levels, while COUPTF2 depletion caused a modest increase in lytic 172 gene expression. Of note, SOX18 depletion had a marked negative effect on LANA mRNA and 173 protein levels while PROX1 depletion reduced LANA transcripts to a half, but only marginally its 174 protein levels ( Fig.3a,b , Supplementary Fig.2a ). KSHV titers were reduced by a half upon PROX1 175 depletion and more severely after SOX18 silencing, while COUPTF2 silencing did not affect the 176 titers, despite the decreased lytic protein expression. 177
178
In KLECs PROX1 depletion did not change SOX18 levels whereas SOX18 depletion decreased the 179 PROX1 mRNA and slightly its protein levels ( Fig.3b, Supplementary Fig.3d ). Since SOX18 180 positively regulates PROX1 during LEC development, we explored the reciprocal effect of depletion 181 of these TFs also in non-infected LECs. In the absence of KSHV, silencing of either PROX1, SOX18 182 or COUPTF2 negatively affected the levels of all the other TFs. This was particularly evident for 183 PROX1 and even more for SOX18. PROX1 expression decreased upon both SOX18 and COUPTF2 184 silencing, and similarly, decreased SOX18 expression upon PROX1 and COUPTF2 depletion was 185 observed in non-infected LECs ( Supplementary Fig.3e ). This suggests that in KLECs KSHV 186 infection has uncoupled the reciprocal regulation of PROX1, SOX18 and COUPTF2 expression. 187
188
Since SOX18 depletion affected not only the lytic genes but also the latent LANA expression, we 189 investigated whether this was due to a diminished number of intracellular viral genomes (episomes). 190
While PROX1 silencing modestly decreased viral episome numbers (by 10%), SOX18 depletion 191 decreased them by about 70% (Fig.3d ), suggesting that SOX18 may contribute to the high episome 192 copies in KLECs. 193 194 Next, we co-silenced PROX1 and SOX18 to test if they reduce KSHV lytic gene expression and titers 195 independently of each other. As a positive control, we also treated KLECs with phosphonoacetic acid 196 (PAA), an inhibitor of the viral DNA polymerase which inhibits the late lytic program and virus 197 production ( Fig.3e,f interfering with the cell cycle 24 , rather than having a SOX18-specific effect. 240
241
To further assess the specificity of the inhibitors, we tested these drugs on the SOX18-negative 242 iSLK.219 cells transduced with a control (myc-NLS-mCherry) or a myc-tagged SOX18-expressing 243 lentivirus. iSLK.219 is a cancer-derived cell line stably infected with rKSHV.219 and expressing 244 KSHV-ORF50 that drives lytic reactivation from a doxycycline (dox)-inducible promoter 25 . In the 245 absence of dox these cells are strictly latent. KSHV episomes were quantified in latently-infected 246 cells or cells reactivated with dox for 48h and treated with the indicated inhibitors or DMSO ( Fig.4e ). 247
SOX18 expression significantly increased KSHV episome copies both in latent and lytic cells. SM4 248 and R(+) propranolol treatments reduced episome copies in iSLK.219 ectopically expressing SOX18 249 but not in the controls, supporting the specificity of the SOX18 chemical inhibition. 250 Therefore, these results provide a proof of principle that targeting SOX18 could represent a future 251 strategy for KS treatment. 
SOX18 binds to the KSHV genome in the proximity of the origins of replication 268
To further investigate the effect of SOX18 on the KSHV episomes, iSLK.219 cells were transduced 269 with the mCherry-or increasing amounts of SOX18-expressing lentiviruses and KSHV episomes 270 were quantified 48h post-transduction ( Fig.5a ). We observed a significant, dose-dependent increase 271 of KSHV episome copy number. We tested whether this was due to increased proliferation of SOX18-272 expressing iSLK.219 by 5-ethynyl-2'-deoxyuridine (EdU) treatment ( Supplementary Fig.5a ). No 273 change in the percentage of proliferating (EdU-positive) cells was found following SOX18 274 expression. Additionally, KSHV gene, protein expression and titers were monitored for 72h in 275 iSLK.219 after dox-induced reactivation ( Supplementary Fig.5b-d ). SOX18 ectopic expression 276 mildly increased KSHV lytic transcripts and proteins without increasing the titers. These data suggest 277 that SOX18 expression increases viral genome copies without increasing cell proliferation and only 278 slightly contributes to lytic gene expression upon dox induction. 279
280
During latency, KSHV replication occurs mainly by a LANA-dependent mechanism from the 281 terminal-repeat (TR) region of the KSHV genome and, to a minor extent, through a LANA-282 independent mechanism from the OriA region, adjacent to the origin of lytic replication (OriLyt) 26, 27 . 283
We measured the activity of luciferase-reporters harbouring either seven copies of the TR region 284 (7XTR) or the OriA fused to OriLyt upstream of an SV40 promoter and a firefly luciferase reporter 285 ( Fig.5b ,c, Supplementary Fig.5e ,f). ORF50, that binds to the OriLyt and is a potent activator of this 286 reporter 28 , was used as a positive control. In the presence of LANA, SOX18 expression increased 287 the activity of the 7XTR reporter in a dose-dependent manner. SOX18 expression also increased the 288 activity of the OriA+OriLyt reporter in an ORF50-independent manner. SOX18 did not change the 289 activity of a reporter plasmid harbouring the ORF50 promoter ( Supplementary Fig.5g,) supporting 290 the specificity of the activation observed in the 7XTR and OriA+OriLyt reporters. 291
Since the reporter assays suggested that SOX18 might bind to the KSHV origins of replication, we 292 assessed this further by ChIP-qPCR in iSLK.219 ectopically expressing a myc-tagged SOX18 293 ( Fig.5d,e ). Binding of SOX18 to the KSHV genome was observed in regions adjacent to the TR and 294 within and adjacent to the OriA region. SOX18 drives EC fate through the regulation of a subset of 295 genes harbouring in their promoter an IR5 consensus motif, composed of two SOX18-binding sites 296 spaced by five nucleotides (nt) 21 . Notably, one of these motifs was located adjacent to the KSHV-297 TR region bound by SOX18 ( Fig.5d ). 298
Overall these results indicate that SOX18 binds at the proximity of KSHV origins of latent replication, 299
and it increases in viral episome copies. expressed during the lytic cycle 29,30 ( Fig.6a, Supplementary Fig.5a ). Analysis of differentially 324 expressed genes (DEG; Supplementary Table1) revealed several cellular pathways involved in 325 oncogenesis (e.g. p53 signalling, viral carcinogenesis, and transcription misregulation in cancer) 326 altered by PROX1 silencing in KLECs ( Supplementary Fig.5b ), supporting the pivotal role of PROX1 327 in KS pathogenesis. Conversely, PROX1 reintroduction in iSLK.219 cells induced with dox led to an 328 overall increase in viral gene expression ( Fig.6a ). The analysis of DEG (Supplementary Table2) in 329 iSLK.219 did not identify differentially regulated pathways. 330
We further characterized iSLK.219 cells transduced with lentiviruses encoding a Myc-tagged 331 PROX1, either WT or a mutant (MUT) harbouring two point mutations at the DNA binding site 332 (N624A and N626A) and lacking transcriptional activity 31 , as well as a control vector. One day after 333 dox-induced lytic reactivation PROX1 WT, but not MUT, expression increased the transcription of 334 lytic KSHV genes and immunoblot analysis revealed higher lytic protein levels in the presence of 335 PROX1 WT ( Supplementary Fig.5c,d) . High-content image analysis in iSLK.219 cells 24h after dox-336 induced reactivation, revealed that PROX1 WT, but not MUT, increased the percentage of cells 337 positive for early (RFP, ORF57) and late (K8.1) lytic markers ( Supplementary Fig.5e ). KSHV titers 338 were significantly higher in iSLK.219 cells expressing PROX1 WT when compared to MUT or 339 controls ( Supplementary Fig.5f ).
These results suggest that, upon lytic reactivation, a 340 transcriptionally active PROX1 increases KSHV lytic gene expression and titers. 341
24
To assess if PROX1 could induce spontaneous lytic reactivation in latent iSLK.219, they were 342 transduced with PROX1 (either WT or MUT) lentiviruses or controls in the absence of dox. This led 343 to about two-to ten-fold increase in lytic mRNAs, but not in lytic proteins ( Supplementary Fig.5g,  344 h). Therefore, we hypothesized that an early viral lytic factor was needed for PROX1 to significantly 345 enhance KSHV lytic cycle. Since KSHV-ORF50 is sufficient to trigger the complete lytic cascade, 346
we investigated whether PROX1 would act in concert with ORF50 to increase the lytic gene 347 expression. We first performed a luciferase-reporter assay using the ORF50 promoter upstream of a 348 luciferase gene (ORF50-luc) and measured its activity upon ectopic expression of PROX1, WT or 349 MUT, or ORF50 expression plasmid alone and in combination with the PROX1 constructs ( Fig.6b , 350 Supplementary Fig.4i ). PROX1 alone did not increase the ORF50 promoter activity beyond the basal 351 levels, in agreement with its inability to induce a strong, spontaneous reactivation in iSLK.219 cells. 352
However, PROX1 WT, but not the transcriptionally inactive MUT, enhanced significantly the 353 ORF50-mediated transcription from its own promoter. We also found that PROX1 WT, but not 354 PROX1 MUT, co-immunoprecipitated ORF50 in iSLK.219 reactivated for 24h by dox-treatment 355 ( Fig.6c ). Furthermore, in LECs infected with WT-KSHV, ORF50 and PROX1 co-localized in the 356 viral replication and transcription compartments 32,33 (Pearson´s correlation coefficient, PCC=0.65, 357 cycle, (Fig.6f) , it did not bind during latency ( Supplementary Fig.5j ). PROX1 binding to the ORF50 363 promoter was also confirmed in KLECs (Fig.6f, lower panel) . observed that 92% of the skin/LN cases (24/26) and 50% (5/10) of the GI-KS were co-expressing 369 PROX1 and K8.1 (Fig.6g ). This suggests that PROX1 expression is associated with KSHV lytic 370 protein expression also in KS tumours. 
KSHV infection of BECs or LECs results to different viral expression programs in the infected cells. 409
While the virus is strictly latent in KBECs, it displays a unique, spontaneous lytic replication program 410 in KLECs 5 . Multiple evidence supports a lymphatic rather than blood endothelial origin for KS-SC 3 . 411
Our findings that SOX18, PROX1 and COUPTF2 are all expressed in KS-SC further support the 412 lymphatic origin of KS-SC. We found that SOX18 and PROX1, both essential for maintaining the 413 LEC identity, regulate KSHV life cycle through two different mechanisms in KLECs. COUPTF2 414 instead, although also expressed in KS, had no role in KSHV replication in KLECs. 415 416 SOX18 is listed among the 1482 genes differentially regulated in KS compared to normal skin 17 , but 417 its role in the KSHV biology has been little explored. Here we show that SOX18 binds to the KSHV 418 episome and increases their number. This is the first time that SOX18 is associated to a key function 419 in viral life cycle. It has so far been linked to the transcriptional regulation of ECs and to the 420 progression of solid cancers 34, 35 . SOX18 forms a dimer 20,21 , able to bind to the viral and cellular 421 genomes. This may lead to a stronger viral episome tethering to the host genome, thus improving the 422 efficiency of KSHV genome retention. Supporting this hypothesis is the finding that SOX18 chemical 423 inhibition of homo and heterodimerization reduced KSHV genomes. While the less characterized 424 SM4 molecule will need further testing, the enantiopure R propranolol has already been proven safe 36 425 and could in principle be repurposed to treat KS patients. 426 427 PROX1 has been studied in KSHV-induced EC reprogramming but little is known about its role in 428 the KSHV life cycle. We found that PROX1 acts at the initiation of KSHV lytic cascade by enhancing 429 transcription from the ORF50 promoter in an ORF50-dependent manner. However, we do not exclude 430 that PROX1 might also govern the expression of cellular regulator(s) of lytic reactivation and/or 431 interact with other viral/cellular products and thereby enhance also other phases of the lytic cycle. 432
433
We further show that the late lytic protein K8.1 is expressed in the majority of the studied KS biopsies, 434
suggesting that, similar to KLECs in culture, lytic protein expression is likely a common feature of 435 KS tumours. This is supported by detection of the lytic proteins K5 and K15 in KS biopsies 37, 38 
Plasmids and lentivirus constructs 500
The following plasmids were used in this study: pAMC Prox1 WT, pAMC Prox1 MUT, pAMC 501 (described in 31 ); pcDNA ORF50 (described in 44 ); pcDNA LANA; pcDNA 3.1 (Thermo Fisher); 502 pGL2-ORF50 (described in 44 ); pGL2-basic (Promega); pGL3-7XTR (provided by TF Schulz, 503
Hannover Medical School) and pGL3-basic (Promega). 504 505 32 PROX1 WT and PROX1 MUT expressing lentiviruses were described previously 20 . The control 506 pFuW-myc-NLS-mCherry was generated from the pFuW-myc-BirA-NLS-mCherry (a kind gift by 507 R.Kivela, University of Helsinki). SOX18 gene sequence was codon optimized and synthesized by 508
GeneArt (Thermo Fisher). The codon optimized SOX18 was cloned in the pFuW-myc by Gibson 509
Assembly using as an initial backbone pFuW-myc-NLS-mCherry. Backbone and insert were 510 assembled using the NEB HiFi DNA assembly (New England BioLabs, E2611). 
Quantification of virus genome copy number 567
Equal number of cells (10 6 ) were harvested and cellular and viral DNA was isolated with NucleoSpin 568
Tissue Kit (Macherey-Nagel, Cat#740988). The extracted DNA was then analysed by qPCR using 569 primers for genomic actin (AGAAAATCTGGCACCACACC; AACGGCAGAAGAGAGAACCA) 570 and K8.1 (AAAGCGTCCAGGCCACCACAGA; GGCAGAAAATGGCACACGGTTAC). 571 572
Co-immunoprecipitation (Co-IP) 573
iSLK.219 cells were transduced with Myc-tagged PROX1 (WT or MUT) lentiviral vectors or an 574 empty pSIN control vector. 24h later cells were reactivated with 0.2 µg/ml doxycycline and one day 575 later cells were lysed in IP buffer (150 mM NaCl, 25 mM tris HCl pH 7,6, 1 mM EDTA, 1% glycerol, 576 0.2% NP-40). 577 578 Pre-cleared lysates were incubated with either mouse monoclonal Myc-tag (1:100) or normal mouse 579 IgG (1:100) antibodies O/N at 4°C with gentle rotation and, subsequently, 30 µl of pre-washed Protein 580 G sepharose beads (ab 193259, Abcam) were added and incubated for 2h at 4°C with gentle rotation. 581
Beads were then washed 3 times in ice-cold IP buffer and the protein complexes analysed by western 582 blot. Experiments were done at least two independent times, representative, cropped blots are shown, 583 uncropped blots are shown in Supplementary Fig.6 . 584 585
Chromatin-immunoprecipitation (ChIP) 586
For each ChIP one 10 cm dish of iSLK.219 cells transduced with the vector of interest were used. 587
The experiments were performed using the Simple ChIP enzymatic chromatin IP kit (Cell Signaling 588
Technology, cat# 9003S ). For chromatin IP the following antibodies were used: rabbit polyclonal 589 anti-PROX1 (Cat#11067-2-AP, Proteintech Group), mouse monoclonal anti-Myc (Cat#2276, Cell 590
Signaling Technology), normal mouse or rabbit IgG (sc-2025 and sc-3888, Santa cruz 591 biotechnology), mouse monoclonal anti-HA.11(16B12, BD Pharmingen). 592
593
The experiments were done at least two independent times, Graphs show the average across the 594 different experiments ±SEM (Fig.5 ) or SD (Fig.6) . 595
596
The isolated DNA was amplified with the following primers: 597 ORF50 -620-850 (F;R) gtggtagagccagcagacgttc; tgtagcgccatctctgccc 598 ORF50 -320-610 (F;R) gggtgatttcttctaccacggtcat; ccgagcgtattctcagaggtct 599 
